waypoint wealth counsel Takes $528,000 Position in Medtronic PLC $MDT

waypoint wealth counsel purchased a new position in Medtronic PLC (NYSE:MDT) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 5,541 shares of the medical technology company’s stock, valued at approximately $528,000.

Several other large investors also recently added to or reduced their stakes in the stock. 1248 Management LLC purchased a new position in shares of Medtronic during the first quarter worth approximately $26,000. Delos Wealth Advisors LLC bought a new position in Medtronic in the second quarter worth approximately $27,000. Twin Tree Management LP purchased a new position in Medtronic during the 1st quarter worth $29,000. Tripletail Wealth Management LLC bought a new stake in Medtronic during the 3rd quarter valued at $34,000. Finally, GFG Capital LLC purchased a new stake in shares of Medtronic in the 2nd quarter worth $36,000. 82.06% of the stock is owned by hedge funds and other institutional investors.

Medtronic Stock Performance

MDT opened at $96.05 on Tuesday. Medtronic PLC has a twelve month low of $79.29 and a twelve month high of $106.33. The firm has a market capitalization of $123.13 billion, a PE ratio of 25.89, a PEG ratio of 2.54 and a beta of 0.71. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The firm’s 50-day moving average price is $97.54 and its 200 day moving average price is $93.86.

Medtronic (NYSE:MDT) last released its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping analysts’ consensus estimates of $1.31 by $0.05. The business had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The business’s revenue was up 6.6% on a year-over-year basis. During the same period last year, the company posted $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, sell-side analysts expect that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 16th. Shareholders of record on Friday, December 26th will be paid a dividend of $0.71 per share. The ex-dividend date of this dividend is Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 3.0%. Medtronic’s payout ratio is 76.55%.

Analyst Upgrades and Downgrades

MDT has been the topic of several research reports. UBS Group raised their price target on Medtronic from $95.00 to $102.00 and gave the company a “neutral” rating in a research note on Wednesday, November 19th. Barclays raised their target price on shares of Medtronic from $109.00 to $111.00 and gave the company an “overweight” rating in a research report on Thursday, November 20th. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a research report on Friday, November 14th. Weiss Ratings reissued a “buy (b)” rating on shares of Medtronic in a report on Monday, December 15th. Finally, Daiwa Capital Markets boosted their price objective on shares of Medtronic from $104.00 to $117.00 and gave the stock a “buy” rating in a research note on Tuesday, November 25th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $109.94.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).